These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20571601)

  • 1. Analysis of neuropsychiatric adverse events during clinical trials of efavirenz in antiretroviral-naive patients: a systematic review.
    Gazzard B; Balkin A; Hill A
    AIDS Rev; 2010; 12(2):67-75. PubMed ID: 20571601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.
    Mills AM; Antinori A; Clotet B; Fourie J; Herrera G; Hicks C; Madruga JV; Vanveggel S; Stevens M; Boven K;
    HIV Med; 2013 Aug; 14(7):391-400. PubMed ID: 23298380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population.
    Nelson M; Stellbrink HJ; Podzamczer D; Banhegyi D; Gazzard B; Hill A; van Delft Y; Vingerhoets J; Stark T; Marks S
    AIDS; 2011 Jan; 25(3):335-40. PubMed ID: 21150563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Safety and Neuropsychiatric Adverse Events Associated With Efavirenz Use in First-Line Antiretroviral Therapy: A Systematic Review and Meta-Analysis of Randomized Trials.
    Ford N; Shubber Z; Pozniak A; Vitoria M; Doherty M; Kirby C; Calmy A
    J Acquir Immune Defic Syndr; 2015 Aug; 69(4):422-9. PubMed ID: 25850607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of trials investigating efavirenz-induced neuropsychiatric side effects and the implications.
    Gaida R; Truter I; Grobler C; Kotze T; Godman B
    Expert Rev Anti Infect Ther; 2016; 14(4):377-88. PubMed ID: 26900637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.
    Muñoz-Moreno JA; Fumaz CR; Ferrer MJ; González-García M; Moltó J; Negredo E; Clotet B
    AIDS Rev; 2009; 11(2):103-9. PubMed ID: 19529750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results.
    Gazzard B; Duvivier C; Zagler C; Castagna A; Hill A; van Delft Y; Marks S
    AIDS; 2011 Nov; 25(18):2249-58. PubMed ID: 21881478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Has the time come to abandon efavirenz for first-line antiretroviral therapy?
    Raffi F; Pozniak AL; Wainberg MA
    J Antimicrob Chemother; 2014 Jul; 69(7):1742-7. PubMed ID: 24603962
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for gastrointestinal adverse events in HIV treated and untreated patients.
    Hill A; Balkin A
    AIDS Rev; 2009; 11(1):30-8. PubMed ID: 19290032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
    Cohen CJ; Andrade-Villanueva J; Clotet B; Fourie J; Johnson MA; Ruxrungtham K; Wu H; Zorrilla C; Crauwels H; Rimsky LT; Vanveggel S; Boven K;
    Lancet; 2011 Jul; 378(9787):229-37. PubMed ID: 21763935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
    Domingo P; Ribera E
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.
    Drury A; Gleadow-Ware S; Gilfillan S; Ahrens J
    Malawi Med J; 2018 Mar; 30(1):40-45. PubMed ID: 29868159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
    Castillo SA; Hernandez JE; Brothers CH
    Drug Saf; 2006; 29(9):811-26. PubMed ID: 16944966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
    Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
    Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
    Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
    Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Valerian in Preventing Neuropsychiatric Adverse Effects of Efavirenz in HIV-Positive Patients: A Pilot Randomized, Placebo-Controlled Clinical Trial.
    Ahmadi M; Khalili H; Abbasian L; Ghaeli P
    Ann Pharmacother; 2017 Jun; 51(6):457-464. PubMed ID: 28478716
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evidence-based therapeutic drug monitoring for efavirenz].
    Solas C; Gagnieu MC;
    Therapie; 2011; 66(3):197-205. PubMed ID: 21819803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discontinuation of efavirenz therapy in HIV patients due to neuropsychiatric adverse effects.
    Leutscher PD; Stecher C; Storgaard M; Larsen CS
    Scand J Infect Dis; 2013 Aug; 45(8):645-51. PubMed ID: 23427878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.